These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10550412)

  • 1. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
    Jönsson B; Cook JR; Pedersen TR
    Diabetologia; 1999 Nov; 42(11):1293-301. PubMed ID: 10550412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
    Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
    CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary heart disease prevention: insights from modelling incremental cost effectiveness.
    Marshall T
    BMJ; 2003 Nov; 327(7426):1264. PubMed ID: 14644970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins: where are we now?
    Cowie MR
    Hosp Med; 2000 Nov; 61(11):789-92. PubMed ID: 11198749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS
    Am Heart J; 1999 May; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin: building on success.
    Gaw A
    Hosp Med; 2001 Jan; 62(1):29-32. PubMed ID: 11211458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
    Goa KL; Barradell LB; McTavish D
    Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions].
    Szucs TD; Lüscher TF; Gutzwiller F
    Schweiz Med Wochenschr; 1997 Nov; 127(44):1819-23. PubMed ID: 9446200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.
    Haffner SM
    Diabetes Care; 1997 Apr; 20(4):469-71. PubMed ID: 9096961
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart protection study: LDL lowering therapy and cardiovascular outcomes in patients with low cholesterol levels or diabetes.
    Kulkarni M; Reaven PD
    Curr Diab Rep; 2002 Jun; 2(3):269-73. PubMed ID: 12643184
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
    Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.
    Briseño GG; Mino-León D
    Curr Med Res Opin; 2010 May; 26(5):1075-81. PubMed ID: 20225991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
    Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
    Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
    Keiding H; Hildebrandt P; Alemao E; Davies GM
    Ugeskr Laeger; 2008 Jun; 170(26-32):2323-6. PubMed ID: 18570764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study.
    Herman WH; Alexander CM; Cook JR; Boccuzzi SJ; Musliner TA; Pedersen TR; Kjekshus J; Pyörälä K
    Diabetes Care; 1999 Nov; 22(11):1771-8. PubMed ID: 10546006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of pharmacologic cholesterol-lowering on the utilization of resources in health care--Significance of the Scandinavian Simvastatin Survival Study for cost reduction under Swiss conditions].
    Steurer J
    Schweiz Med Wochenschr; 1998 Jul; 128(29-30):1150-1. PubMed ID: 9715503
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.